 Cooped-up people around the world have been clinging to the hope that a vaccine that will quell the Covid-19 pandemic can be developed quickly. Biotech company Moderna Inc.'s stock soared this week after it announced promising results from a trial of its coronavirus vaccine — news that was quickly tempered by the company's failure to release data that could back up its claims. With the cratering global economy unlikely to recover until a viable vaccine or treatment can be discovered, it was a bleak reminder that medical progress is not a straight, fast-moving line — and no one can achieve it on their own. Vaccine Developers Like Moderna Need to Take Their Time — Max Nisen Eradicating Covid-19 Might Justify Risky Vaccine Trials — Editorial Board A Vaccine With a Poison Pill — Matt Levine Moderna Fiasco Shows Power of Stock Market Narratives — John Authers This Was a Big Week in Coronavirus Immunity — Faye Flam AstraZeneca Is Caught Up in Delicate Vaccine Politics — Chris Hughes Moderna Vaccine Whiplash Demands Better Disclosure — Max Nisen America Has Opted for a Bad Recession — Narayana Kocherlakota The U.S. Can't Defeat Coronavirus Alone — Editorial Board It's a Good Time to Raise Vaccine Money — Matt Levine This is the Theme of the Week edition of Bloomberg Opinion Today, a roundup of our top commentary published every Sunday. | 
Post a Comment